Home Biosimilar Antibodies Metabolism PCSK9 inhibitor Alirocumab (anti-PCSK9)
For research use only. Not for use in humans.

Alirocumab (anti-PCSK9)

Alirocumab (anti-PCSK9) works by inhibiting the PCSK9 protein, which binds to the low-density lipoprotein receptor (LDLR) and causes receptor degradation, removing less LDL cholesterol from the circulation.

Alirocumab (anti-PCSK9)

Click to purchase the isotype control of Alirocumab (anti-PCSK9)

Quality Control

Batch: A204701 Purity: 98% Protein concentration: 4.3mg/ml Endotoxin Level: <1 EU/mg
98

Specificity

Name Citation PCSK9
PF-06446846 0
PF-06446846 hydrochloride 0
SBC-110736 0
R-IMPP 0
SBC-115076 9
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Alirocumab (anti-PCSK9) works by inhibiting the PCSK9 protein, which binds to the low-density lipoprotein receptor (LDLR) and causes receptor degradation, removing less LDL cholesterol from the circulation.

Product Details

CAS No. 1245916-14-6
Molecular Weight 150 kDa
Isotype human IGg1, κ
Application Alirocumab (anti-PCSK9)
Source CHO
Purification Protein G
Sterility 0.2 μM filtered
Formulation PBS Buffer, PH 7.4
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.